Q2 2025 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) reported a 6% year-over-year volume growth for EXPAREL, marking the highest growth in eight quarters.
- The company enhanced its capital structure and liquidity with a new $300 million revolver and significant debt reduction.
- Pacira BioSciences Inc (PCRX) executed a transformative collaboration with Johnson & Johnson MedTech for ZILRETTA, potentially expanding reach and patient access.
- The company increased its full-year guidance for non-GAAP gross margins to 78% to 80%, benefiting from improved manufacturing efficiencies.
- Pacira BioSciences Inc (PCRX) is on track to reach 60 million covered commercial lives by the end of the year, enhancing EXPAREL's market access.
- The company reported a shift in vial mix and discounting, which partially offset the 6% volume growth for EXPAREL.
- Non-GAAP SG&A expenses increased to $77.2 million, up from $59 million last year, due to investments in commercial and market access initiatives.
- The guidance range for full-year revenue was narrowed, indicating potential challenges in achieving the upper end of previous expectations.
- The adoption of EXPAREL in formularies could take 6 to 12 months, potentially delaying revenue realization.
- Despite progress, the company faces uncertainties in achieving tipping points for commercial payer adoption of the NOPAIN reimbursement model.
Good day, and thank you for standing by. Welcome to the Pacira Biosciences Q2 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Susan Mesco, Head of Investor Relations. Please go ahead.
Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our second quarter 2025 financial results. Joining me are Frank Lee, Chief Executive Officer; Brendan Teehan, Chief Commercial Officer; and Shawn Cross, Chief Financial Officer. Tony Malloy, Chief Legal and Compliance Officer, is also here for today's question and answer session.
Before we begin, let me remind you that this call will include forward-looking statements subject to the safe harbor provisions of federal securities laws. Such statements represent our judgment as of today and may involve risks and uncertainties. This may cause our actual results, performance, or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
